文献速递炎症性肠病消化道肿瘤与早癌

基于人群的匹配队列研究:炎症性肠病患者与无IBD人群的消化外癌症发病率与死亡率

A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease.
PubMed 文献 · Aliment Pharmacol Ther · 2025-11-11

该研究利用加拿大安大略省1994–2020年行政数据,比较110,919例IBD患者与1:10年龄性别匹配对照的消化外癌症发病率与死亡率。IBD患者消化外癌症年发病率保持稳定,而对照下降;2010–2020年IBD患者消化外癌症发病率更高,克罗恩病患者癌症相关死亡率更高。

要点

  • IBD患者消化外癌症年发病率稳定,匹配对照则下降。
  • 2010–2020年IBD患者消化外癌症发病率高于对照(SIR 1.20)。
  • 克罗恩病患者消化外癌症相关死亡率高于对照(SMR 1.31)。

核心结论

  • IBD患者消化外癌症发病率未变而对照下降,2010年后IBD患者发病率更高且克罗恩病患者死亡率更高。

研究设计与样本

  • 基于加拿大安大略省人群行政数据的匹配队列研究,纳入1994–2020年110,919例IBD患者与1,109,190例年龄性别匹配(1:10)无IBD对照。

主要发现

  • IBD患者消化外癌症年发病率平均年度百分比变化为0.108%/年(95% CI -0.380, 0.599),对照为-1.39%/年(95% CI -1.57, -1.21)。
  • IBD患者中非霍奇金淋巴瘤(1.48%/年;95% CI 0.161, 2.82)、黑色素瘤(1.77%/年;95% CI 0.781, 2.77)、宫颈癌(2.31%/年;95% CI 0.602, 4.10)、子宫癌(4.41%/年;95% CI 0.045, 8.96)和甲状腺癌(8.10%/年;95% CI 4.31, 12.0)的发病率变化显著。
  • 2010–2020年IBD患者消化外癌症发病率高于对照(SIR 1.20;95% CI 1.15, 1.26)。
  • 克罗恩病患者消化外癌症相关死亡率高于对照(SMR 1.31;95% CI 1.14, 1.51)。

关键数值与推荐

  • IBD患者消化外癌症发病率SIR 1.20(95% CI 1.15, 1.26),克罗恩病患者死亡率SMR 1.31(95% CI 1.14, 1.51),均为2010–2020年与匹配对照比较。

临床怎么用

  • 对IBD患者应关注消化外癌症风险,尤其2010年后及克罗恩病患者,需结合人群数据优化监测策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trends in extra-digestive (ED) cancer incidence and mortality in inflammatory bowel diseases (IBD) may be changing with newer approaches to management. AIMS: To study temporal trends and contemporary risks of ED cancers in individuals with and without IBD. METHODS: Using population-level administrative data from Ontario, Canada, we studied ED cancer rates among individuals with IBD and age-sex-matched controls (1:10) without IBD between 1994 and 2020. We modelled age-sex-standardised annual cancer incidence (per 100,000 person-years) over time by first-order linear autoregression, and standardised cancer incidence and mortality rate ratios (SIR, SMR) by quasi-Poisson regression. RESULTS: The average annual percentage change (AAPC) in ED cancer incidence was stable among 110,919 people with IBD (0.108%/year; 95% CI, -0.380, 0.599) but declined among 1,109,190 matched controls (-1.39%/year; 95% CI, -1.57, -1.21). Among those with IBD, AAPC was significant for non-Hodgkin's lymphoma (1.48%/year; 95% CI, 0.161, 2.82), melanoma (1.77%/year; 95% CI, 0.781, 2.77), cervical (2.31%/year; 95% CI, 0.602, 4.10), uterine (4.41%/year; 95% CI, 0.045, 8.96) and thyroid (8.10%/year; 95% CI, 4.31, 12.0) cancers, and statistically greater than controls for cervical, ovarian, lung, and bladder cancers. During 2010-2020, ED cancer incidence was higher in those with IBD (SIR 1.20; 95% CI 1.15, 1.26), while ED cancer-related mortality was specifically higher in those with Crohn's disease (CD; SMR 1.31; 95% CI 1.14, 1.51), as compared to matched controls. CONCLUSIONS: ED cancer incidence has not changed among those with IBD but has declined among matched controls. Beyond 2010, ED cancer incidence is higher among those with IBD and cancer-related mortality is higher among those with CD, relative to matched controls.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Murthy SK, Ahmed F, Pugliese M, et al. A Population-Based Matched Cohort Study of Extra-Digestive Cancer Incidence and Mortality in Individuals With and Without Inflammatory Bowel Disease. Aliment Pharmacol Ther. 2025. PMID: 41215713. doi:10.1111/apt.70439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。